Navigation Links
Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
Date:6/19/2012

NEW YORK, June 19, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that its upcoming Analyst Day will be webcast live on Thursday, June 21, 2012 at 4:30 pm ET. Scheduled speakers include:

Julia Lewis, M.D., will provide her perspective on the Zerenex (ferric citrate) Phase 3 clinical program and the potential Zerenex product profile.
-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine.

Geoffrey Block, M.D., will discuss the potential for Zerenex in pre-dialysis.
-- Director of Research, Denver Nephrology and Associate Clinical Professor in Medicine, University of Colorado Health Sciences Center.

David Goldfarb, M.D., will discuss the potential importance of citrate.
-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.

To access the live audio webcast, please visit the Company's Investor Relations section of their website (http://investors.keryx.com). An archived version of the webcast will become available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City. 
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
4. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
5. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
6. OncoSec Announces Issuance of New Patent for Method of Use
7. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
8. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
9. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
10. UK supplier of graphenes announces exclusive sales agency agreement with leading USA distributor
11. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , Nov. 27, 2014 ... the "Global Palmitic Acid Industry Report 2014" ... The Global Palmitic Acid Industry ... the current state of the global palmitic acid industry. ... the industry including definitions, classifications, applications and industry chain ...
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... The North America Thermal Protective Clothing Market ... analysis of the growth trends and revenue forecasts. ... by 2018, growing at a CAGR of 7.1% ... TOC of the North America Thermal Protective Clothing ... in-depth analysis and industry segmentation supported by various ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2
... May 11, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... ended March 31, 2009. Arena reported a net loss allocable ... $50.6 million, or $0.68 per share, compared to a net ... 2008 of $55.0 million, or $0.75 per share. "Receiving the ...
... Inc. (Nasdaq: IDIX ) announced today that Idenix ... Bank 2009 Health Care Conference on Monday, May 18, 2009 ... and archived webcast of the company presentation can be accessed ... www.idenix.com . Please log in approximately ...
... 18, 2009 SAN DIEGO, May 11 Neurocrine Biosciences, ... Kevin Gorman, President and Chief Executive Officer of Neurocrine ... Annual Health Care Conference in Boston. The live presentation ... Eastern Time (ET)/2:05 p.m. Pacific Time (PT). The ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference 2
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Hospital (MGH) Cancer Center have identified a subgroup of ... drug cisplatin, rarely used in the treatment of breast ... of this sensitivity, which may help identify patients most ... will be tested in a clinical trial anticipated to ...
... delivered into the tumors of stage 4 lung cancer ... phase I clinical trial at The University of Texas ... found to be active in the metastatic non-small cell ... first-in-human study and we've seen an exciting proof of ...
... cut back on the amount of salt in their diet could ... to a report on bmj.com today. , Researchers in ... risk of death from cardiovascular disease by up to a fifth. ... diseases linked to the heart or arteries, for example a stroke ...
Cached Biology News:Molecular signature may identify cisplatin-sensitive breast tumors 2Molecular signature may identify cisplatin-sensitive breast tumors 3Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer 2Eating less salt could prevent cardiovascular disease 2
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
Biology Products: